This Week in European MedTech and HealthTech: 13th March 2026
- Nelson Advisors
- 14 minutes ago
- 5 min read
European HealthTech this week is dominated by EU‑level regulatory moves around MDR/IVDR and AI, plus a clear pivot of digital health from “experiments” to scaled implementation and validation funding.
EU regulatory and policy moves
The Commission has advanced a 2026 Health Package revising MDR/IVDR to ease bottlenecks: more predictable conformity assessment, codified “Helsinki procedure” for borderline products, and risk‑based (rather than fixed 5‑year) certificate validity.
Cybersecurity is being hard‑wired into MDR/IVDR, with obligations to report actively exploited vulnerabilities and severe cyber incidents in medical devices within 30 days, aligning with broader EU cyber rules.
Digitalisation provisions will allow EU declarations of conformity and some IFUs in digital‑only form and require fully electronic submissions into EUDAMED; four core EUDAMED modules went live in late 2025, triggering a transition to mandatory use from May 2026.
EU machinery for joint clinical assessments under the HTA Regulation is now live, with more MedTech expected to enter the pipeline during 2026, raising the bar for clinical evidence in market access dossiers.
AI Act, SaMD and medical AI
Work is ongoing to integrate AI Act “high‑risk” obligations with MDR/IVDR so high‑risk medical AI can go through a single sectoral conformity route, avoiding duplicated certification; core AI Act obligations are expected to apply from around August 2026.
Recent analysis and events (e.g. EUCROF’s focus on SaMD and AI) highlight that MDR and the upcoming AI Act are reshaping compliance and commercialisation strategies for software as a medical device, including real‑world examples such as Healthentia.
Industry and policy fora this week (e.g. “Masters of Digital 2026”, MWC/4YFN “AI in Healthcare: Hype or Hope?”) are centering on AI governance in care delivery and diagnostics rather than just technical capabilities.
Market environment, exits and consolidation
EU data show sustained pressure on MedTech innovation portfolios, with reduced pipelines, cancelled launches and some manufacturers exiting EU markets due to MDR/IVDR cost and complexity, which is pushing resource re‑allocation and go/no‑go decisions.
Analysts expect consolidation driven by regulatory complexity, with larger hardware incumbents and big tech acquiring software/data innovators to secure “compliance moats” and data sovereignty under the evolving EU regulatory stack.
At CES 2026, European AI‑driven MedTech companies were already positioning offerings for US reimbursement and institutional contracting, underlining continued internationalisation despite home‑market frictions.
Funding, grants and validation capital
Global Health EDCTP3 has opened 2026 calls with up to €147m across six topics (TB, LRTIs, HIV/co‑morbidities, climate‑linked infectious disease), explicitly supporting digital/clinical innovation and data‑/AI‑heavy platforms.
Within the Horizon Europe 2026–27 work programme, a substantial part of a €14bn R&I envelope is earmarked for health and digital technologies, reinforcing medium‑term grant support for AI, data and platform‑driven health innovation.
EIT Health just launched its 2026 Innovation Validation Call, funding up to 50% of project budgets (max €850k) to accelerate clinical validation, regulatory approval and market launch for late‑stage digital, data and AI‑driven healthcare innovations.
Ecosystem, infrastructure and events
Analysis this week frames European digital health as entering a “proof through exits” phase, with investor focus shifting from round size to scalability, regulatory readiness and clear paths to liquidity.
health.tech 2026 in Basel and European Digital HealthTech‑linked events are emphasizing implementation: deploying AI in workflows, prevention systems, and aligning with EHDS, SaMD/AI regulation, and procurement rules.
There is renewed emphasis on EHR maturity and interoperability as prerequisites for scaling teleconsultations and virtual care; WHO experts underline that robust EHR infrastructure is essential for digital health service expansion.
To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email lloyd@nelsonadvisors.co.uk
>>>>
European MedTech this week is centred on the EU “Health Package” (MDR/IVDR reset plus biotech/clinical trials tweaks), upcoming Commission discussions on devices, and a continued narrative of consolidation and “compliance‑driven” strategy.
MDR/IVDR “regulatory reset”
The Commission has proposed targeted amendments to MDR and IVDR to simplify requirements, reduce administrative burden and improve notified body predictability, responding to evidence of reduced pipelines, cancelled launches and exits from the EU market.
Key elements include more proportionate, risk‑based rules (e.g. updated classification such as a refined Rule 11 for software), removal of fixed certificate validity in favour of validity limited only when risk justifies it, and priority review paths for breakthrough or orphan devices.
Manufacturers would benefit from clearer rules on post‑certification changes, structured dialogue with notified bodies, digital Declarations of Conformity and eIFUs, and reduced PSUR frequency, with fee reductions and support measures for micro and small enterprises.
Timelines and stakeholder input
The legislative proposal is at EU co‑decision stage; it must be adopted by Parliament and Council and may be amended during the process.
An eight‑week feedback window is open into mid‑March 2026 for stakeholders to comment on the MDR/IVDR changes, with submissions shared with EU legislators.
In parallel, AI Act implementation work continues, with plans to allow high‑risk medical AI to use a single MDR/IVDR‑anchored conformity route rather than duplicative AI Act certification when obligations overlap.
Innovation, safety and procurement agenda
On 16 March 2026, the Commission will host a high‑level conference in Brussels on “Medical Devices: Innovation and Patient Safety,” covering predictability of conformity assessment, the role of expert panels in clinical evidence, and guidance for breakthrough technologies.
New EU proposals are also set to reshape procurement for MedTech and diagnostics, which could materially affect pricing, value‑based criteria and access for both incumbents and innovators.
The EU HTA Regulation machinery is now operational, and more MedTech is expected to enter joint clinical assessments in 2026, raising the evidentiary bar for pan‑EU market access.
Market structure, M&A and capital
Analysts highlight ongoing pressure on MedTech innovation portfolios from MDR/IVDR‑driven costs and complexity, prompting portfolio pruning and re‑prioritisation of launches.
A distinct “compliance‑driven M&A” theme is emerging, with strategics acquiring targets partly to secure regulatory “compliance moats” and de‑risk EU market access, while PE pursues buy‑and‑build strategies in fragmented segments.
Transatlantic capital flows remain strong, with US corporate and growth funds active in European robotics and AI‑driven MedTech, helping to bridge the historical Series B+ gap and allowing companies to scale further before exit.
Internationalisation and AI‑driven MedTech
European AI‑driven MedTech players are increasingly designing offerings around US reimbursement and institutional contracting, as showcased at CES 2026, reflecting a push to scale outside Europe while regulatory reforms work through at home.
Upcoming European events (e.g. Athens Digital Health Week, European Digital HealthTech Conference) are being used as coordination points on EHDS implementation and SaMD/AI adoption in routine care, which directly impacts device‑plus‑software business models.
To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email lloyd@nelsonadvisors.co.uk
Nelson Advisors > European MedTech and HealthTech Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital
Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb
Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Comments